妊娠期甲状腺功能异常的检测、监测与治疗
妊娠期甲亢和甲减均可对母胎造成不良影响。妊娠期甲状腺毒症最常见病因为妊娠一过性甲状腺毒症和Graves病,两者治疗不同,需鉴别。育龄期Graves病患者应接受治疗选择对妊娠影响的咨询。抗甲状腺药物虽有致畸绝对风险小,但丙硫氧嘧啶致畸性似低于甲巯咪唑,妊娠早期需用药时优选丙硫氧嘧啶。放射性碘后应建议推迟妊娠至少6个月。甲减与不良产科和子代神经发育结局相关,临床甲减应左甲状腺素治疗使TSH<2.5 mIU/L。母体低甲状腺素血症和亚临床甲减与流产、早产和子代认知评分较低相关,但轻度甲状腺功能减退的治疗仍存争议。
要点
- 妊娠期甲亢需鉴别妊娠一过性甲状腺毒症与Graves病,治疗不同
- 妊娠早期需抗甲状腺药物时优选丙硫氧嘧啶,其致畸性似低于甲巯咪唑
- 临床甲减应左甲状腺素治疗,TSH目标<2.5 mIU/L
核心结论
- 妊娠期甲亢和甲减均可导致不良结局,需检测、监测并个体化治疗。
- 临床甲减应左甲状腺素治疗使TSH<2.5 mIU/L;轻度甲状腺功能减退治疗仍存争议。
- 妊娠期甲状腺毒症需鉴别妊娠一过性甲状腺毒症与Graves病以指导治疗。
研究设计与样本
- 本文为J Clin Endocrinol Metab发表的综述,汇总妊娠期甲状腺功能异常的检测、监测与治疗证据。
主要发现
- 妊娠期甲状腺毒症最常见病因为妊娠一过性甲状腺毒症和Graves病。
- 抗甲状腺药物有致畸效应,绝对风险小;丙硫氧嘧啶致畸性似低于甲巯咪唑。
- 甲减与不良产科和子代神经发育结局相关。
- 母体低甲状腺素血症和亚临床甲减与流产、早产和子代认知评分较低相关。
关键数值与推荐
- 临床甲减应左甲状腺素治疗,TSH目标<2.5 mIU/L。
- 妊娠早期如需抗甲状腺药物,优选丙硫氧嘧啶。
- 放射性碘治疗后建议推迟妊娠至少6个月。
- 育龄期Graves病患者应咨询治疗选择对妊娠的影响。
临床怎么用
- 妊娠期应检测甲状腺功能,鉴别甲亢病因以选择治疗。
- 临床甲减启动左甲状腺素治疗并监测TSH至<2.5 mIU/L。
- 妊娠早期需抗甲状腺药物时优先选用丙硫氧嘧啶。
- 放射性碘治疗后建议避孕至少6个月,确保甲状腺激素水平正常后再妊娠。
局限性
- 轻度母体甲状腺功能减退的治疗仍存争议,缺乏显示左甲状腺素治疗改善结局的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Both hyperthyroidism and hypothyroidism can have adverse effects in pregnancy. The most common causes of thyrotoxicosis in pregnancy are gestational transient thyrotoxicosis and Graves' disease. It is important to distinguish between these entities as treatment options differ. Women of reproductive age who are diagnosed with Graves' disease should be counseled regarding the impact of treatment options on a potential pregnancy. Although the absolute risk is small, antithyroid medications can have teratogenic effects. Propylthiouracil appears to have less severe teratogenicity compared to methimazole and is therefore favored during the first trimester if a medication is needed. Women should be advised to delay pregnancy for at least 6 months following radioactive iodine to minimize potential adverse effects from radiation and ensure normal thyroid hormone levels prior to conception. As thyroid hormone is critical for normal fetal development, hypothyroidism is associated with adverse obstetric and child neurodevelopmental outcomes. Women with overt hypothyroidism should be treated with levothyroxine (LT4) to a thyrotropin (thyroid-stimulating hormone; TSH) goal of <2.5 mIU/L. There is mounting evidence for associations of maternal hypothyroxinemia and subclinical hypothyroidism with pregnancy loss, preterm labor, and lower scores on child cognitive assessment. Although there is minimal risk of LT4 treatment to keep TSH within the pregnancy-specific reference range, treatment of mild maternal thyroid hypofunction remains controversial, given the lack of clinical trials showing improved outcomes with LT4 treatment.
引用
- Lee SY, Pearce EN. Testing, Monitoring, and Treatment of Thyroid Dysfunction in Pregnancy. J Clin Endocrinol Metab. 2021. PMID: 33349844. doi:10.1210/clinem/dgaa945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。